-+ 0.00%
-+ 0.00%
-+ 0.00%

BIOMEA FUSION ANNOUNCES POSITIVE 52-WEEK RESULTS FROM PHASE 2 COVALENT-112 TRIAL IN TYPE 1 DIABETES SHOWING C-PEPTIDE IMPROVEMENT AND DURABILITY FOLLOWING 12-WEEKS OF ICOVAMENIB TREATMENT

Reuters·04/27/2026 21:37:38

Please log in to view news